An evaluation of SNP frequency, aspirin resistance, and adenoma/colorectal cancer risk in the PLCO study
Principal Investigator
Name
Holli Loomans-Kropp
Degrees
Ph.D., M.P.H.
Institution
The Ohio State University
Position Title
Assistant Professor
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
PLCO-978
Initial CDAS Request Approval
May 9, 2022
Title
An evaluation of SNP frequency, aspirin resistance, and adenoma/colorectal cancer risk in the PLCO study
Summary
A significant body of epidemiologic evidence suggests the preventive effects of long-term aspirin use for colorectal cancer. However, aspirin use does not prevent all colorectal cancers. To gain further insight into the genetic mechanisms through which aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), we propose to evaluate the association between single nucleotide polymorphism (SNP) frequency, aspirin/NSAID use, and colon adenoma and colorectal cancer risk. The results of this study will add knowledge to our understanding of aspirin resistance or sensitivity in cancer prevention.
Aims
Aim 1: An evaluation of the association between aspirin/NSAID use, SNP frequency and adenoma risk
Research question 1: What is the association between PLCO-examined SNPs and adenoma risk among aspirin users, compared to non-aspirin users?
Research question 2: What is the association between PLCO-examined SNPs and adenoma risk among NSAID users, compared to non-NSAID users?
Aim 2: An evaluation of the association between aspirin/NSAID use, SNP frequency and colorectal cancer risk
Research question 1: What is the association between PLCO-examined SNPs and colorectal cancer risk among aspirin users, compared to non-aspirin users?
Research question 2: What is the association between PLCO-examined SNPs and colorectal cancer risk among NSAID users, compared to non-NSAID users?
Aim 3: Compare significant SNPs found in Aim 1 to those found in Aim 2.
Collaborators
Asad Umar (National Cancer Institute), Paul Pinsky (National Cancer Institute), Daoud Meerzaman (National Cancer Institute)